Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
NRIX
NRIX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
NRIX News
Wall Street Analysts Adjust META Stock Outlook
Jan 29 2026
Benzinga
Ark Invest Unveils 2026 Big Ideas, Forecasts 1.9% GDP Growth Boost
Jan 21 2026
Benzinga
Oncolytics Biotech Accelerates Cancer Treatment with New Executive Appointments
Jan 14 2026
Newsfilter
Oncolytics Biotech Accelerates Cancer Treatment Progress, Aiming for FDA Approval in 2026
Jan 14 2026
PRnewswire
Evercore ISI Upgrades Roku to Outperform, Raises Price Target to $145
Jan 08 2026
CNBC
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
Dec 24 2025
Globenewswire
Major Stocks on the Rise Monday: Paramount Skydance, Wave Life Sciences, Ocular Therapeutix, Carvana, and More
Dec 08 2025
Benzinga
Nurix Reports Bexobrutideg Clinical Data with 83% ORR in CLL Patients
Dec 06 2025
Globenewswire
Nurix Reports Bexobrutideg Clinical Data with 83% ORR in CLL Patients
Dec 06 2025
Newsfilter
Nurix Therapeutics to Host Webcast on December 8 to Review BTK Degrader Clinical Data
Dec 01 2025
Globenewswire
Nurix Therapeutics Welcomes Esteemed Biopharmaceutical Executive Roger Dansey, M.D., to Its Board of Directors
Nov 10 2025
Newsfilter
Nurix Therapeutics Unveils New Translational Findings from First Human Clinical Trial of Oral CBL-B Inhibitor NX-1607, Highlighting Immune Activation and Tumor Microenvironment Changes
Nov 07 2025
Newsfilter
Insights from 13 Analysts on Nurix Therapeutics
Nov 04 2025
Benzinga
Needham Affirms Buy Rating on Nurix Therapeutics, Keeps $26 Price Target Intact
Nov 04 2025
Benzinga
BTIG Affirms Buy Rating for Nurix Therapeutics, Keeps $27 Price Target Intact
Nov 04 2025
Benzinga
Nurix Therapeutics Completes $250 Million Public Stock Offering with Underwriting
Oct 27 2025
Yahoo Finance
Show More News
